Omeros Corp. buy marge
Zusammenfassung
Diese Einschätzung wurde am 05.11.21 mit einem Endkurs von 6,20 € beendet. Die BUY Einschätzung von marge schloss mit einer Rendite von -58,16 %. marge hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
Name | 1W | 1M | 1J | 3J |
---|---|---|---|---|
Omeros Corp. | 18,95 % | 18,95 % | -44,76 % | -71,72 % |
iShares Core DAX® | 0,80 % | 2,12 % | 15,59 % | 16,56 % |
iShares Nasdaq 100 | 1,99 % | 4,07 % | 28,81 % | 56,20 % |
iShares Nikkei 225® | 1,26 % | -2,37 % | 3,37 % | 4,27 % |
iShares S&P 500 | 1,64 % | 2,29 % | 24,19 % | 46,90 % |
Kommentare von marge zu dieser Einschätzung
In der Diskussion Omeros Corp. diskutieren
Orphan drug market support blockbuster potential for OMS721
The company's pipeline is progressing very well and it has released
positive results for three separate compounds in mid-stage trials in the
month of October. It has also addressed funding needs. Omeros has also
been reiterated as a Buy by five different analyst firms during the
month after little activity from the analyst community on this name
throughout 2016. Price targets proffered were all at least double the
current price of the stock as well. The overall range was from $19 to $75 a share.
In der Diskussion Trading Omeros Corp.